Co-authored with Tufts Medical Center postdoctoral researcher Hamad Al Ibrahim, MD, PhD, of Qatar University, the paper outlines reforms in research funding, study design and reporting practices aimed at closing longstanding gaps in care and outcomes for women.
The article, “Precision Medicine’s Blind Spot: Rebalancing the Evidence Base to Reflect Women’s Health,” examines how decades of underrepresentation of women in biomedical research continue to shape modern clinical practice. While precision medicine is designed to tailor prevention, diagnosis and treatment to individual patients, the authors argue that this promise cannot be fully realized when sex differences are not consistently measured, analyzed or reported.
Bird and Al Ibrahim identify persistent structural challenges. Women remain underrepresented in many clinical trials; conditions that disproportionately affect women receive comparatively less research funding, and sex-disaggregated analyses are still inconsistently required or published. These gaps can translate into delayed diagnoses, missed treatment opportunities and avoidable disparities in outcomes.
The paper highlights clinical areas where the consequences are especially visible, including cardiovascular disease, autoimmune disorders and maternal health. For example, women are more likely than men to experience delayed or incorrect diagnosis following a heart attack, and patients with autoimmune diseases, which disproportionately affect women, often wait years for an accurate diagnosis. Together, these patterns underscore the cost of an incomplete evidence base.
To address these gaps, the authors call for stronger requirements for sex-disaggregated analysis, research designs that incorporate sex differences from the outset, greater investment in women’s health research and broader efforts to diversify the scientific workforce and clinical trial participation.
The work is already shaping national conversations. In April, Dr. Bird presented the findings in a keynote address to the National Institutes of Health Advisory Committee for Research on Women’s Health, highlighting opportunities to strengthen the scientific foundation of precision medicine and improve health outcomes across the lifespan. Building on this momentum, the team is now actively quantifying gaps in the evidence base on cardiovascular disease, systematically identifying where sex-specific data are missing, underreported or inconsistently analyzed to better inform research priorities and clinical practice.
As Dr. Bird notes, “When we fail to consistently measure and analyze sex differences, we are building medical knowledge on an incomplete foundation. Closing these gaps is not a niche concern—it is essential to improving outcomes for everyone.”
She and her co-authors also emphasize that the implications extend beyond equity alone. “Research on women’s health is among the most scientifically and clinically impactful areas of biomedical inquiry,” Bird added. “Yet persistent gaps in the evidence base carry enormous costs in health outcomes, in research efficiency and in economic burden. Addressing them has the potential to be transformative.”
By challenging longstanding assumptions and advocating for more rigorous, inclusive research practices, the authors aim to ensure that the next generation of medical discovery benefits all patients—not just those historically best represented in research.
As a leader in women’s health research, Tufts Medicine is tackling some of the most critical gaps in medicine today. Your generosity helps accelerate discoveries that improve diagnosis, treatment and outcomes for women and shape the future of healthcare for everyone.
Join us in advancing the next breakthrough.
